ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2
Jenna K. Dick, Venkatramana Divana Krishna, Dustin Hicks…·Geoffrey T. Hart
This study shows that Fc receptor engagement is necessary for the efficacy of SARS-CoV-2 therapeutics, including mAbs and BiKEs, and demonstrates the effectiveness of ACE2 decoy Fc-fusions and BiKEs against multiple variants.